Abstract
Ganciclovir-resistant (GanR) cytomegalovirus (CMV) infection after organ transplantation is emerging as a significant therapeutic challenge. We report two cases of GanR CMV infection successfully managed by switching immunosuppression from calcineurin inhibitors to an mTOR inhibitor-based regimen. This salvage therapy should be considered when other options are not available.
© 2012 The Authors. Transplant International © 2012 European Society for Organ Transplantation.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiviral Agents / pharmacology
-
Calcineurin Inhibitors
-
Cytomegalovirus / metabolism*
-
Cytomegalovirus Infections / drug therapy*
-
Drug Resistance, Viral*
-
Ganciclovir / pharmacology*
-
Heart Transplantation / adverse effects
-
Humans
-
Immunosuppressive Agents / pharmacology*
-
Kidney Transplantation / adverse effects
-
Male
-
Middle Aged
-
Organ Transplantation / adverse effects
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Calcineurin Inhibitors
-
Immunosuppressive Agents
-
MTOR protein, human
-
TOR Serine-Threonine Kinases
-
Ganciclovir